Akari Therapeutics Plc Stock Price, News & Analysis

Akari Therapeutics, Plc (Nasdaq: AKTX) announced it has been granted an additional 180-day compliance period by Nasdaq, extending the deadline to regain compliance with the minimum bid price requirement until October 23, 2023. To maintain its listing, Akari must keep a minimum closing bid price of $1.00 per share for at least ten consecutive business days. There is no immediate impact on the company’s Nasdaq listing, and its American Depository Shares will continue to be traded. Akari is focused on developing advanced therapies for autoimmune diseases, with lead investigational asset nomacopan undergoing Phase 3 trials for pediatric HSCT-TMA. The company holds Orphan Drug and Fast Track designations from the FDA for this treatment.

On April 14, 2023, Akari Therapeutics (Nasdaq: AKTX) announced a virtual key opinion leader event scheduled for May 22, 2023, at 2 PM ET. This session will delve into the treatment landscape for geographic atrophy (GA) and the potential of long-acting PAS-nomacopan, an investigational therapy aimed at addressing significant unmet needs in this area. The event will feature Dr. Elias Reichel from Tufts University School of Medicine, who will discuss the development program for PAS-nomacopan. Following the presentations, a live Q&A session will be held. Interested individuals can register for the event through the provided link, and a replay will be available on the Akari website.

Akari Therapeutics is focused on developing advanced therapies for autoimmune and inflammatory diseases, with nomacopan as its lead asset. The company has received various designations for nomacopan related to its pediatric healthcare applications.

Akari Therapeutics, Plc (Nasdaq: AKTX) is set to participate in ARVO 2023 from April 23 to 27 in New Orleans. The event gathers around 10,000 professionals in vision research to discuss advancements in the field. Akari’s primary focus is on its investigational drug, nomacopan, a bispecific inhibitor targeting complement C5 and leukotriene B4, currently in pre-clinical development for geographic atrophy. Akari is also advancing nomacopan through a Phase 3 trial for pediatric HSCT-TMA, supported by FDA designations including Orphan Drug and Fast Track. The company aims to connect with researchers and potential partners at ARVO 2023 to drive innovation in autoimmune and inflammatory disease therapies.

Akari Therapeutics (Nasdaq: AKTX) announced a case study presentation titled Clinical Response to Nomacopan in the Paediatric HSCT-TMA Setting, scheduled for April 23, 2023, during the European Society for Blood and Marrow Transplantation (EBMT) in Paris. Nomacopan, an investigational bispecific inhibitor, is currently in Phase 3 clinical trials targeting pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA). The company plans to advance into pivotal Part B trials later this year. Akari holds multiple FDA designations for nomacopan and is developing it for both pediatric and adult indications.

Akari Therapeutics (Nasdaq: AKTX) has secured approximately $4 million in gross proceeds through a direct offering involving institutional and accredited investors, including its Board of Directors. The company will issue around 26.67 million American Depository Shares (ADSs) at a price of $0.15 per ADS. Proceeds will fund two key pipeline initiatives: advancing a Phase 3 trial for nomacopan in severe pediatric conditions and a preclinical study for geographic atrophy. The offering excludes warrants and is expected to close on March 31, 2023.